Cancer Cell Panel Screening, a platform involving the screening of test agents on cells with diverse genomic backgrounds, has emerged as a comprehensive tool for oncology therapeutic development. It provides critical insights into the identification of cell lines that exhibit high sensitivity to certain test agents, the exploration of drug mechanisms, and the evaluation of the efficacy of combination therapies.
Comprehensive Cancer Cell Line Selection: Access over 600 cancer cell lines, including more than 100 engineered KO, KI, and drug-resistant cancer lines. Custom panels for targets like KRAS, WRN, DDR, PARP, and HER2 are available, with flexible screening options.
2D and 3D Viability Assays and Diverse Assay Offerings: Measure cell viability using 2D/3D CellTiter-Glo® assays for precise IC50/GI50 determination. A wide range of assays, including colony formation, cell cycle analysis, and apoptosis studies. All assays come with no timeline restrictions, and combination studies are also available.
RNA-Seq and Advanced Bioinformatics: Gain actionable insights with our RNA sequencing services, analyzing drug response and resistance mechanisms in both sensitive and resistant cancer cell lines.
In Vivo CDX Models: Evaluate drug efficacy in in vivo CDX models using our special gene engineered cell lines for more predictive, real-world data.
Expert Consultation and Tailored Solutions: Get personalized guidance from our experts to choose the best cell lines and panels for your study.
Plate Formats: 96-well plate / 384-well plate
Assay Formats: CellTiter-Glo, CyQUANT, Hoechst, Ki67
Assay Conditions: 10% FBS or 2%-5% FBS (serum concentration)
Number of Doses: 10 doses (IC50 or GI50 format)
Number of Replicates: Duplicate
Compound Treatment Duration:
- 3 days, 5 days, 7 days, or extended time
- At least 2 cell doubling times
- Custom durations based on client preferences
Comprehensive Documentation: Detailed methods and testing conditions
Quality Control Metrics: Z' factor, Signal-to-Window (SW), Coefficient of Variation (CV%), Reference compound data
Experimental Results: % Inhibition, curve fitting, and IC50 values (calculated using XLfit or GraphPad Prism, if applicable)
- Combination Studies
- Target Engagement Assays
- Cell Apoptosis Assays, Cell Cycle Analysis, Protein Phosphorylation Assays
- Xenograft Models
Choose from over 500 human tumor cell lines available in our ICE cell bank, with an ongoing addition of cell lines per month. Collaborators have the flexibility to select specific cell lines of interest from our cell bank to create a tailored Cell Panel for screening.
ICE Bioscience has established a predefined cell panel comprising 170 tumor cell lines, covering 21 cancer types. This cell panel can be utilized for screening sensitive cell lines against test agents, exploring new drug indications, and conducting toxicity screening. ICE also has a bioinformatics team and a cell line information database to support both early- and late-stage bioinformatics analyses of the cell panel.
Our bioinformatic analysis of drug-resistant cell lines based on RNA-seq. Using our internal algorithms, we can provide detailed differential gene expression information, enrichment pathways, and characteristic gene profiles.
Our specialized panels include targeting DDR, RAS, EGFR, and HER2 cell lines. These panels are designed to facilitate mechanism of action studies, and drug sensitivity testing, providing powerful tools to accelerate therapeutic development.
We value your inquiries and are here to provide you with tailored solutions for your drug discovery and development needs. Whether you have questions, require more information, or are interested in discussing potential collaborations, our team of experts is just a message away.
Feel free to reach out to us.
